Welcome to our dedicated page for Thermo Fishr Sci SEC filings (Ticker: TMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scanning 200+ pages for gene-sequencing revenue or biopharma service margins in Thermo Fisher Scientific’s reports is a real challenge. The company’s multi-segment model—life science reagents, analytical instruments, specialty diagnostics, and contract manufacturing—creates complex footnotes that most investors can’t decode quickly.
Our platform solves that problem. Every Thermo Fisher Scientific SEC filing is captured the moment it hits EDGAR, then parsed by Stock Titan’s AI. Whether you need the Thermo Fisher Scientific quarterly earnings report 10-Q filing for segment trends, or you’re following Thermo Fisher Scientific insider trading Form 4 transactions to spot leadership confidence, we provide plain-English explanations, key metrics, and red-flag alerts. You’ll also find Thermo Fisher Scientific Form 4 insider transactions real-time and automatic summaries that make understanding Thermo Fisher Scientific SEC documents with AI straightforward.
Use this page to: track acquisition disclosures with Thermo Fisher Scientific 8-K material events explained; dive into R&D and goodwill accounting through the Thermo Fisher Scientific annual report 10-K simplified; evaluate board pay with the latest Thermo Fisher Scientific proxy statement executive compensation; or perform a quick Thermo Fisher Scientific earnings report filing analysis minutes after release. Real-time alerts, AI-generated highlights, and historical search let you follow Thermo Fisher Scientific executive stock transactions Form 4 and compare trends across quarters without wading through technical jargon.
Thermo Fisher Scientific (Finance I) B.V., a Dutch finance subsidiary of Thermo Fisher Scientific Inc., plans to issue euro-denominated floating-rate and fixed-rate senior notes fully and unconditionally guaranteed by Thermo Fisher. The floating notes will pay interest at 3‑month EURIBOR plus a spread with a zero floor, while the fixed notes pay a set annual coupon; both are unsecured senior obligations with no sinking fund.
Thermo Fisher intends to use the euro notes’ net proceeds for general corporate purposes, which may include acquisitions, debt repayment or refinancing, working capital, capital expenditures and share repurchases. The company recently agreed to acquire Clario Holdings, Inc. for $8.875 billion in cash plus up to $525 million of additional and contingent consideration, and in October 2025 issued $2.5 billion of U.S. dollar senior notes for similar corporate uses.
The notes are expected to be listed on the New York Stock Exchange and cleared through Euroclear and Clearstream. Key features include optional redemption for the fixed notes, tax-related redemption rights, a change-of-control repurchase at 101% of principal plus interest, and payment of additional amounts to address specified Dutch and U.S. withholding taxes.
Thermo Fisher Scientific Inc. (TMO) senior vice president and chief financial officer Stephen Williamson reported an insider transaction involving company common stock. On 11/14/2025, he transferred 433 shares of Thermo Fisher common stock in a transaction coded "G," which indicates a gift, at a reported price of $0 per share. Following this transaction, he beneficially owned 31,887.193 shares of common stock directly. He also had 12,674 shares reported as indirectly owned through a SLAT, and he disclaims beneficial ownership of those indirect shares except to the extent of any pecuniary interest.
Thermo Fisher Scientific (TMO) reported an insider transaction by its Sr. VP and Chief HR Officer. On 11/12/2025, the officer sold 1,057.577 shares of common stock at a price of $588.265 per share (Transaction Code S).
Following the sale, the officer’s beneficial ownership is 13,087.227 shares, held directly. No derivative securities were reported in this filing.
Thermo Fisher Scientific (TMO) reported an insider transaction by EVP & COO Michel Lagarde. On 11/13/2025, he exercised 4,638 stock options at $253.99 per share (code M), acquiring common stock, and then sold 4,638 shares at a $594.42 weighted average price (code S). Following these transactions, his directly held common stock was 23,479.909 shares. The sale price reflected multiple trades between $594.36 and $594.88. The option, with a $253.99 exercise price, was originally scheduled to vest in four equal installments on February 26 of 2020–2023 and carried an expiration of 02/26/2026.
TMO: A holder filed a Form 144 notice to sell up to 4,638 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 11/13/2025.
The filing lists an aggregate market value of 2,756,934.94 for the proposed shares and notes 375,708,059 shares outstanding. The shares to be sold were acquired via an option granted on 02/26/2019 and paid in cash on 11/13/2025.
Thermo Fisher Scientific (TMO) received a Form 144 notice for a proposed sale of up to 1,058 common shares through Fidelity Brokerage Services, with an aggregate market value of $622,135.54. The shares are expected to be sold on the NYSE around 11/12/2025.
The securities were acquired via restricted stock vesting: 1,016 shares on 02/23/2022 and 42 shares on 08/25/2023. A related table shows 10,225 common shares were sold on 11/07/2025 for gross proceeds of $5,844,850.08. Shares outstanding were 375,708,059.
Thermo Fisher Scientific (TMO) reported insider transactions by an Executive Vice President on 11/10/2025 under a Rule 10b5-1 trading plan. The officer exercised 725 options at $253.99 and 2,250 options at $294.02, then sold 725 shares and 2,250 shares at $580.
Following these transactions, the officer beneficially owned 21,152.223 shares of common stock, held directly. The options exercised were previously granted and had vested in four equal annual installments ending in 2023.
Thermo Fisher Scientific (TMO) reported insider transactions by an officer (Sr. VP and Chief HR Officer) on 11/07/2025. The filer sold 1,750 shares of common stock at $571.3977, exercised 8,475 stock options at $253.99, and sold 8,475 shares at $571.6701. Following these trades, the filer directly owned 14,144.804 shares.
The exercised option related to a grant that vested in four equal installments on February 26, 2020, 2021, 2022, and 2023.
Thermo Fisher Scientific (TMO) insider Gianluca Pettiti filed a Form 144 to sell up to 2,975 shares of common stock on or about 11/10/2025 on the NYSE through Fidelity Brokerage Services. The filing lists an aggregate market value of $1,725,500. The shares derive from options granted in 2019 and indicate cash exercise on 11/10/2025. The notice also reports a prior sale of 400 shares on 10/24/2025 for $229,660. Shares outstanding were 375,708,059, a baseline figure.
Thermo Fisher Scientific (TMO) filed a Form 144 notice for a proposed sale of common stock by an affiliated holder. The filing lists 10,225 shares to be sold with an aggregate market value of $5,844,850.08, through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 11/07/2025.
The shares come from a mix of equity awards, including 8,475 shares from an option granted on 02/26/2019 (paid in cash on 11/07/2025) and multiple restricted stock vestings totaling 1,750 shares from 2021–2024. As context, shares outstanding were 375,708,059 at the time referenced in the notice; this is a baseline figure, not the amount being offered.
FAQ
What is the current stock price of Thermo Fishr Sci (TMO)?
What is the market cap of Thermo Fishr Sci (TMO)?
